Supportive Care Intervention for Brain Cancer
Trial Summary
What is the purpose of this trial?
This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis. The main question this study aims to answer is whether this intervention (which includes access to an information guide and one-on-one coaching sessions) is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in the coaching sessions, use the guide as desired, and complete a small group of short surveys at three different points in time; some participants will be asked to share feedback via exit interviews.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on providing support and information, so it's unlikely that medication changes are required.
What data supports the effectiveness of the treatment Information and Support Intervention, NeuroPathways Intervention, Information and Support Intervention for Brain Tumor Patients?
Research shows that providing tailored information and support can help brain cancer patients and their caregivers feel more informed and supported, which can improve their overall experience and satisfaction with care. Similar approaches have been effective in meeting the supportive care needs of patients with other types of cancer, like breast cancer, by providing education and psychological support.12345
Is the Supportive Care Intervention for Brain Cancer safe for humans?
The available research does not provide specific safety data for the Supportive Care Intervention for Brain Cancer or its related interventions. However, the studies suggest that participants generally found the interventions helpful and were satisfied with them, indicating no major safety concerns were reported.16789
How is the I-CoPE supportive care treatment for brain cancer different from other treatments?
Research Team
Deborah Forst, MD
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
This trial is for adults over 18 who are patients at Massachusetts General Hospital Cancer Center, recently diagnosed (within 6 weeks) with a primary malignant brain tumor and can speak and read English. It's not suitable for those unable to consent due to severe cognitive issues or if their oncologist thinks it's inappropriate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive an intervention guide and participate in four weekly or biweekly individual sessions with a clinician.
Follow-up
Participants are monitored for psychological, behavioral, and cognitive outcomes, and complete surveys at baseline, 8 weeks, and 12 weeks.
Open-label extension (optional)
Participants may continue to receive supportive care and participate in exit interviews.
Treatment Details
Interventions
- Information and Support Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor